MOTS-c, or Mitochondrial Open Reading Frame of the 12S rRNA-c, is a small peptide encoded within the mitochondrial genome. It is composed of 16 amino acids and is synthesized naturally in the body, with research focusing on its potential roles in cellular metabolism and longevity. The peptide has garnered interest due to its unique origin from mitochondrial DNA, contrasting with the majority of peptides encoded by nuclear DNA. Researchers have explored its synthesis both in vitro and in vivo to understand its biological functions and therapeutic potential. The primary research areas for MOTS-c include its effects on metabolic regulation, insulin sensitivity, and age-related diseases. Researchers have observed that MOTS-c can enhance glucose metabolism and improve insulin action, making it a candidate for addressing metabolic disorders such as obesity and type 2 diabetes. Additionally, studies have suggested potential anti-aging effects, as MOTS-c may influence pathways related to longevity and cellular stress responses. The mechanism of action of MOTS-c involves the activation of the AMPK pathway, a key regulator of energy homeostasis. By modulating this pathway, MOTS-c influences metabolic processes and cellular stress responses, contributing to its observed effects on metabolism and longevity. Researchers have also investigated its interaction with nuclear receptors and other signaling molecules. Pharmacokinetic properties of MOTS-c are still under investigation. Researchers have found that it has a relatively short half-life, with stability and bioavailability varying by administration route. Subcutaneous and intravenous routes have been studied, but detailed pharmacokinetic data remain limited. Current research on MOTS-c is in the preclinical stage, with ongoing studies to elucidate its full therapeutic potential. It is not yet approved for clinical use, and regulatory bodies have not classified it as a medicinal product. Further research is needed to establish its safety and efficacy in humans.